Fig. 6

In vivo fate of ADSCs during RA treatment. (A) ADSCs were sorted by flow cytometry. (B) ADSCs retrieval efficacy on days 2, 4, and 7. (C) PCA analysis of ADSCs retrieved at different timepoints. (D) Heatmap of differentially expressed genes among ADSCs retrieved at different days. (E) GO analysis of gene cluster A. (F) GO analysis of gene cluster B. (G) GO analysis of gene cluster C. (H-L) Enriched GO terms of upregulated genes in (H) 2-day-ADSCs vs. 0-day-ADSCs, (I) 4-day-ADSCs vs. 2-day-ADSCs, (J) 7-day-ADSCs vs. 4-day-ADSCs, and downregulated genes in (K) 7-day-ADSCs vs. 2-day-ADSCs, (L) 7-day-ADSCs vs. 0-day-ADSCs. Differentially Expressed genes included in E-L were screened using the criteria log2FC > 1, Padj < 0.05